Clear Search

Showing 2 results for “DORIS” published 2023.

September 2023

Health Related Quality of Life, Remission and Low Lupus Disease Activity State in Patients with Systemic Lupus Erythematosus

Rheumatology (Oxford). 2023 doi: 10.1093/rheumatology/kead407 Epub ahead of print

One of the first studies to investigate associations between disease activity and QoL, using validated generic and disease-specific PRO questionnaires, found that DORIS remission and LLDAS were associated with significant and clinically relevant higher QoL in most PRO domains of the LupusPRO (disease specific) and SF-36 (generic) questionnaires, but not with LupusQoL and SLEQOL disease-specific questionnaires.

more…

April 2023

Does Remission in Systemic Lupus Erythematosus According to the 2021 DORIS Definition Match the Treating Rheumatologist’s Judgment?

Rheumatology (Oxford) 2023;63(1):72–8 doi: 10.1093/rheumatology/kead159

Assessment on agreement between the 2021 DORIS and physician-judged lupus activity finds the 2021 DORIS remission to be an achievable target in clinical practice, with substantial agreement between the DORIS definition and physician-judged remission.

more…